The following information is intended as a resource for journalists only and was factually correct at the time it was issued.
Follow AbbVie UK
Atopic Dermatitis Factsheet
Sep 13, 2018 14:06 BST
Background information on the skin condition Atopic Dermatitis
AbbVie Presents Upadacitinib Longer-Term (32-Week) and Patient-Reported Outcomes Data from Phase 2b Atopic Dermatitis Study at 27th European Academy of Dermatology and Venereology (EADV) Congress